Baseline characteristics in the Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE)

Journal of the Renin-angiotensin-aldosterone System : JRAAS
Hans-Henrik ParvingALTITUDE Investigators

Abstract

Patients with type 2 diabetes are at enhanced risk for macro- and microvascular complications. Albuminuria and/or reduced kidney function further enhances the vascular risk. We initiated the Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE). Aliskiren, a novel direct renin inhibitor, which lowers plasma renin activity, may thereby provide greater cardio-renal protection compared with angiotensin converting enzyme inhibitor (ACEi) or angiotensin receptor blocker (ARB) alone. ALTITUDE is a randomized, double-blind, placebo-controlled study in high risk type 2 diabetic patients receiving aliskiren 300 mg once daily or placebo added to recommended cardio-renal protective treatment including ACEi or ARB, but not both. The number of patients randomized was 8606. Baseline characteristics (median, IQR) are: age 65 (58, 72) years, male 68%, BMI 29.1 (25.7, 32.2) kg/m(2), cardiovascular disease 47.9%, blood pressure 134.7 (126, 150)/74.3 (67, 81) mmHg, HbA(1c) 7.5 (6.6, 8.6)%, LDL-cholesterol 2.4 (1.9, 3.0) mmol/L, haemoglobin 130 (119, 143) g/L, serum creatinine 115 (91, 137) µmol/L, eGFR 51.7 (42, 65) ml/min per 1.73 m(2), geometric mean UACR 198.9 (52, 2886) mg/g and frequency of micro/macroalbuminuria 25.7% a...Continue Reading

References

Sep 22, 2001·The New England Journal of Medicine·E J LewisUNKNOWN Collaborative Study Group
Sep 22, 2001·The New England Journal of Medicine·B M BrennerUNKNOWN RENAAL Study Investigators
Sep 22, 2001·The New England Journal of Medicine·H H ParvingUNKNOWN Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria Study Group
Sep 24, 2004·The New England Journal of Medicine·Nagesh S AnavekarMarc A Pfeffer
Sep 24, 2004·The New England Journal of Medicine·Alan S GoChi-yuan Hsu
Oct 24, 2006·Lancet·Jan A StaessenTom Richart
Feb 8, 2008·The New England Journal of Medicine·Peter GaedeOluf Pedersen
Apr 2, 2008·The New England Journal of Medicine·UNKNOWN ONTARGET InvestigatorsCraig Anderson
Jun 6, 2008·The New England Journal of Medicine·Hans-Henrik ParvingUNKNOWN AVOID Study Investigators
Jun 19, 2008·Circulation·Naomi D L FisherNorman K Hollenberg
Jan 16, 2009·Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association·Hans-Henrik ParvingMarc A Pfeffer
Mar 6, 2010·Hypertension Research : Official Journal of the Japanese Society of Hypertension·David L Feldman
Sep 24, 2010·Kidney International·János Peti-Peterdi
Oct 12, 2010·The New England Journal of Medicine·Sophia ZoungasUNKNOWN ADVANCE Collaborative Group
Feb 15, 2011·European Heart Journal·Scott D SolomonUNKNOWN Aliskiren Study in Post-MI Patients to Reduce Remodeling (ASPIRE) Investigators
Mar 5, 2011·Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association·Henrik ReinhardPeter K Jacobsen
Mar 26, 2011·Journal of the American Society of Nephrology : JASN·Lisa R Stow, Michelle L Gumz
Jul 2, 2011·Journal of the American Society of Nephrology : JASN·Roland E SchmiederUNKNOWN ONTARGET Investigators
Jul 28, 2011·BMJ : British Medical Journal·David Preiss, Kausik K Ray

❮ Previous
Next ❯

Citations

Dec 19, 2012·Nature Reviews. Nephrology·Hiddo J Lambers HeerspinkGerjan J Navis
Oct 31, 2013·Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association·Hiddo J Lambers HeerspinkDick de Zeeuw
Jun 6, 2013·Current Opinion in Cardiology·Susanne B NicholasKeith C Norris
Jun 13, 2013·Medical Science Monitor : International Medical Journal of Experimental and Clinical Research·Sławomir LizakowskiBolesław Rutkowski
Mar 9, 2013·Pediatric Nephrology : Journal of the International Pediatric Nephrology Association·Damien Noone, Christoph Licht
Dec 12, 2012·Cardiovascular Drugs and Therapy·Thomas G von Lueder, Henry Krum
Jun 28, 2014·Current Hypertension Reports·David Parra, Augustus Hough
Jan 23, 2013·Current Atherosclerosis Reports·Chiara Recarti, Thomas Unger
Mar 8, 2014·Advances in Chronic Kidney Disease·Frederik Persson, Peter Rossing
Apr 23, 2013·Maturitas·Georgia ArgyrakopoulouChristodoulos Stefanadis
Dec 1, 2012·Kidney International Supplements
May 21, 2013·American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation·Sandra J TalerRaymond R Townsend
Sep 6, 2012·The Journal of Clinical Hypertension·Lawrence R Krakoff
Mar 21, 2012·European Journal of Heart Failure·John J V McMurrayHenry Krum
Mar 17, 2015·American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions·Patrick Blin
Jan 16, 2015·Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences·Sylwia Magiera, Jacek Kusa
Oct 20, 2012·Journal of Pharmacological Sciences·Paulo Caleb Junior Lima SantosAlexandre Costa Pereira
Oct 25, 2013·Journal of Human Hypertension·J DeiuliisS Rajagopalan
Dec 12, 2012·Journal of the Renin-angiotensin-aldosterone System : JRAAS·Men-Tai WuChien-Te Lee
Mar 8, 2013·European Journal of Preventive Cardiology·P A SminkH J Lambers Heerspink
Apr 1, 2018·Diabetes, Obesity & Metabolism·Hiddo J L HeerspinkDick de Zeeuw
Feb 28, 2020·The Cochrane Database of Systematic Reviews·Meaghan LunneyPietro Ravani
Nov 2, 2016·Journal of the American Society of Nephrology : JASN·Tobias F KröpelinHiddo J L Heerspink
Feb 12, 2021·BMJ : British Medical Journal·Ali AlbasriUNKNOWN STRATIFY investigators

❮ Previous
Next ❯

Clinical Trials Mentioned

NCT00549757

Software Mentioned

ALTITUDE
ASPIRE
ONTARGET
ALLAY

Related Concepts

Related Feeds

Antihypertensive Agents: Mechanisms of Action

Antihypertensive drugs are used to treat hypertension (high blood pressure) which aims to prevent the complications of high blood pressure, such as stroke and myocardial infarction. Discover the latest research on antihypertensive drugs and their mechanism of action here.

Cardiovascular Inflammation

Inflammation plays a significant role in the development of cardiovascular diseases, an understanding of these endogenous processes is critical for evaluating the risks and potential treatment strategies. Discover the latest research on cardiovascular inflammation here.

CV Disorders & Type 2 Diabetes

This feed focuses on the association of cardiovascular diseases in patients with type 2 diabetes.

Cardiovascular Disease Pathophysiology

Cardiovascular disease involves several different processes that contribute to the pathological mechanism, including hyperglycemia, inflammation, atherosclerosis, hypertension and more. Vasculature stability plays a critical role in the development of the disease. Discover the latest research on cardiovascular disease pathophysiology here.

Cardiac Remodeling

Cardiac remodeling in response to a myocardial infarction is characterized by progressive ventricular dilatation, cardiac hypertrophy, fibrosis, and deterioration of cardiac performance. Discover the latest research on Cardiac Remodeling here.

Biomarkers for Type 2 Diabetes

Biomarkers can help understand chronic diseases and assist in risk prediction for prevention and early detection of diseases. Here is the latest research on biomarkers in type 2 diabetes, a disease in which the body is unable to produce or properly use insulin.